PMID- 24779526
OWN - NLM
STAT- MEDLINE
DCOM- 20150527
LR  - 20220311
IS  - 1814-1412 (Electronic)
IS  - 1562-2975 (Linking)
VI  - 15
IP  - 7
DP  - 2014 Sep
TI  - Long-acting injectable risperidone and oral antipsychotics in patients with 
      schizophrenia: results from a prospective, 1-year, non-interventional study 
      (InORS).
PG  - 534-45
LID - 10.3109/15622975.2014.902990 [doi]
AB  - OBJECTIVE: To explore differences in outcomes for patients with schizophrenia 
      treated with risperidone long-acting treatment (RLAT) or oral antipsychotics 
      (oAP). METHODS: The International Observational Registry on Schizophrenia (InORS) 
      explored flexible doses of newly initiated RLAT and oAPs for adults with 
      schizophrenia, exploring 6-month retrospective hospitalization data and 12-month 
      prospective medication use, outcomes, and tolerability. Efficacy outcomes 
      included hospitalizations, the Clinical Global Impression of Schizophrenia 
      (CGI-SCH), and the Global Assessment of Functioning (GAF). Medication switch 
      patterns were also analysed. RESULTS: Data were analysed from 1083 patients (561 
      RLAT, 522 oAP). At baseline, RLAT patients had higher symptom severity, greater 
      functional impairment, and poorer compliance. Percentages of patients 
      hospitalized were similar between groups, and median duration per hospitalization 
      decreased after RLAT initiation and with oAP. The difference in duration of 
      hospitalization between the retrospective and prospective period was 
      significantly better with RLAT (P = 0.002). Mean CGI-SCH change from baseline was 
      significantly better for RLAT vs. oAP patients for overall, positive, and 
      negative symptom scores (P < 0.05). Mean functional improvement from baseline was 
      significantly higher with RLAT vs. oAP (P < 0.001). CONCLUSIONS: Hospitalizations 
      and symptomatic and functional outcomes were better with RLAT vs. oAP; frequent 
      medication switches were associated with less favourable outcomes.
FAU - Schreiner, Andreas
AU  - Schreiner A
AD  - Medical & Scientific Affairs EMEA , Janssen-Cilag GmbH, Neuss , Germany.
FAU - Svensson, Anders
AU  - Svensson A
FAU - Wapenaar, Robert
AU  - Wapenaar R
FAU - Cherubin, Pierre
AU  - Cherubin P
FAU - Princet, Patricia
AU  - Princet P
FAU - Serazetdinova, Larisa
AU  - Serazetdinova L
FAU - Zink, Mathias
AU  - Zink M
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140429
PL  - England
TA  - World J Biol Psychiatry
JT  - The world journal of biological psychiatry : the official journal of the World 
      Federation of Societies of Biological Psychiatry
JID - 101120023
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage/adverse effects/*pharmacology
MH  - Delayed-Action Preparations
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Risperidone/*administration & dosage/adverse effects/*pharmacology
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - long-acting risperidone
OT  - long-term treatment
OT  - observational
OT  - oral antipsychotics
OT  - schizophrenia
EDAT- 2014/05/02 06:00
MHDA- 2015/05/28 06:00
CRDT- 2014/05/01 06:00
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2015/05/28 06:00 [medline]
AID - 10.3109/15622975.2014.902990 [doi]
PST - ppublish
SO  - World J Biol Psychiatry. 2014 Sep;15(7):534-45. doi: 
      10.3109/15622975.2014.902990. Epub 2014 Apr 29.